Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.
TLDR
Drugs treating the multiple pathologies and clinical symptoms in AD (e.g., M1 cholinoceptor and/or galaninergic drugs) should be considered for a more comprehensive treatment approach for cholinergic dysfunction.Abstract:
Alzheimer's disease (AD) is characterized by a progressive phenotypic downregulation of markers within cholinergic basal forebrain (CBF) neurons, frank CBF cell loss and reduced cortical choline acetyltransferase activity associated with cognitive decline. Delaying CBF neurodegeneration or minimizing its consequences is the mechanism of action for most currently available drug treatments for cognitive dysfunction in AD. Growing evidence suggests that imbalances in the expression of NGF, its precursor proNGF and the high (TrkA) and low (p75(NTR)) affinity NGF receptors are crucial factors underlying CBF dysfunction in AD. Drugs that maintain a homeostatic balance between TrkA and p75(NTR) may slow the onset of AD. A NGF gene therapy trial reduced cognitive decline and stimulated cholinergic fiber growth in humans with mild AD. Drugs treating the multiple pathologies and clinical symptoms in AD (e.g., M1 cholinoceptor and/or galaninergic drugs) should be considered for a more comprehensive treatment approach for cholinergic dysfunction.read more
Citations
More filters
Journal ArticleDOI
The cholinergic system in aging and neuronal degeneration.
Reinhard Schliebs,Thomas Arendt +1 more
TL;DR: Observed changes in the expression of NGF, its precursor proNGF, the high and low NGF receptors, trkA and p75NTR, respectively, changes in acetylcholine release, high-affinity choline uptake, as well as alterations in muscarinic and nicotinic acetyl choline receptor expression may contribute to the cholinergic dysfunction.
Journal ArticleDOI
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
Harald Hampel,M.-Marsel Mesulam,A. Claudio Cuello,Martin R. Farlow,Ezio Giacobini,George T. Grossberg,Ara S. Khachaturian,Andrea Vergallo,Enrica Cavedo,Peter J. Snyder,Peter J. Snyder,Zaven S. Khachaturian +11 more
TL;DR: The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as the authors look ahead to future combination therapies that address symptoms as well as disease progression.
Journal ArticleDOI
The Effects of Arsenic Exposure on Neurological and Cognitive Dysfunction in Human and Rodent Studies: A Review
TL;DR: This review will focus on the current epidemiological evidence of arsenic neurotoxicity in children and adults, with emphasis on cognitive dysfunction, including learning and memory deficits and mood disorders, and new studies focusing on therapeutic strategies to combat arsenic toxicity including the use of selenium and zinc.
Journal ArticleDOI
Nicotinic ACh receptors as therapeutic targets in CNS disorders
TL;DR: The functional makeup and expression of the nAChRs in mammalian brain, and their role as targets in neurodegenerative diseases, neurodevelopmental disorders, and neuropathic pain are discussed.
Journal ArticleDOI
Drug treatments in Alzheimer's disease.
TL;DR: Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials and results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution.
References
More filters
Journal ArticleDOI
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
Justin C. McArthur,Constantin T. Yiannoutsos,David M. Simpson,Bruce T. Adornato,Elyse J. Singer,Harry Hollander,Camillo Marra,Michael Rubin,Bruce A. Cohen,Tarvez Tucker,Bradford A. Navia,Giovanni Schifitto,David Katzenstein,C. A. Rask,Lawrence Zaborski,Mary E. Smith,S. Shriver,Linda Millar,David B. Clifford +18 more
TL;DR: A positive effect of recombinant human nerve growth factor on neuropathic pain and pin sensitivity in HIV-associated sensory neuropathy was found and rhNGF was safe and well tolerated, but injection site pain was frequent.
Journal ArticleDOI
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
Oscar L. Lopez,James T. Becker,Stephen R. Wisniewski,Judy A. Saxton,Daniel I. Kaufer,S. T. DeKosky +5 more
TL;DR: There was an initial cognitive and functional benefit from the use of CEIs in Alzheimer's disease, which waned as the disease progressed, however, the results suggest that there is a long term beneficial effect of the useof CEIs, as indicated by the delay in adsmission to nursing homes.
Journal ArticleDOI
Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease.
Michelle L. Gilmor,Jeffrey D. Erickson,Hélène Varoqui,Louis B. Hersh,David A. Bennett,Elizabeth J. Cochran,Elliott J. Mufson,Allan I. Levey +7 more
TL;DR: The data suggest that cholinergic neurons, and the coexpression of ChAT and VAChT, are relatively preserved in early stages of AD.
Journal ArticleDOI
Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection
JK Morse,Stanley J. Wiegand,Keith D. Anderson,Y You,Ning Cai,J Carnahan,J Miller,Peter S. DiStefano,C A Altar,Ronald M. Lindsay +9 more
TL;DR: Brain-derived neurotrophic factor has a substantial capacity to rescue axotomized cholinergic neurons when delivered effectively, according to the patterns of distribution of radiolabeled BDNF and NGF injected into the lateral ventricle.
Journal ArticleDOI
NGF induction of NGF receptor gene expression and cholinergic neuronal hypertrophy within the basal forebrain of the adult rat
TL;DR: The results suggest that NGF produces cholinergic neuronal hypertrophy through induction of NGF-R gene expression within the basal forebrain.
Related Papers (5)
Selective loss of central cholinergic neurons in alzheimer's disease
Peter Davies,A.J.F. Maloney +1 more
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Mark H. Tuszynski,Mark H. Tuszynski,Leon J. Thal,Leon J. Thal,Mary Pay,David P. Salmon,Hoi Sang U,Roy A.E. Bakay,Piyush M. Patel,Armin Blesch,H. Lee Vahlsing,H. Lee Vahlsing,Gilbert Ho,Gang Tong,Steven G. Potkin,James H. Fallon,Lawrence A. Hansen,Elliott J. Mufson,Jeffrey H. Kordower,Christine M. Gall,James M. Conner +20 more